Tango Therapeutics, Inc. (TNGX)

NASDAQ • Healthcare

$23.34

-$4.59 (-16.4%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$25.54

Previous Close$23.34

Day Range$22.68 - $25.94

Avg. Volume (3M)4.4M

Market Cap$3.9B

52 Week Range

$7.12$34.39

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

$53.8M

Net Income (TTM)

-$123.7M

EPS (TTM)

-$0.85

ROA (TTM)

-11.52%

Current Ratio

50.82

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

0.0%Q3 2025-$0.35

+1200.0%Q4 2025$0.13

+6.5%Q1 2026-$0.29

-2.0%Q2 2026-$0.32

-16.6%Q3 2026-$0.37

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -16.6%

Tango Therapeutics’ preliminary results for the second fiscal quarter of 2026, reported August 10, showed a wider loss and EPS that trailed consensus, with EPS of $-0.37 trailing the $-0.32 estimate (-17%) and down from $-0.35 a year ago. Net income was a loss of roughly $55.3 million, down 42.4% year over year from a loss of about $38.9 million, alongside an operating loss of about $59.8 million. The company generated negative operating cash flow of roughly $38.9 million in the quarter. For the next period, consensus calls for EPS of $-0.34 on revenue of $3.3 million.

Next report — what to expect

Tango Therapeutics, Inc. (TNGX) reports on November 3, 2026. Wall Street is looking for consensus EPS of -$0.34 on revenue of $3.3 million. For trailing context, revenue was -100.0% year over year last quarter. The company has beaten EPS in 3 of 8 most recent quarters.

View full earnings history

About Tango Therapeutics, Inc.

Tango Therapeutics, Inc. is a NASDAQ-listed biotechnology company developing precision cancer medicines around defined genetic vulnerabilities. Trading as TNGX, it focuses on oncology drug candidates for tumor types selected by specific mutations and alterations, and it operates as a small-cap therapeutic developer in the healthcare sector.

Name

Tango Therapeutics, Inc.

CEO

Malte Peters

Website

www.tangotx.com

Industry

Healthcare

Year Founded

2017

Employees

137

Today's Snapshot

AI-generated

TNGX closed 16.4% lower at 23.34, in line with a weaker sector. Shares changed hands at roughly three times its usual level. Tango Therapeutics shared Phase 1/2 results for vopimetostat, an experimental cancer drug, in pancreatic and lung cancers.

Trading Volume

Above 10d avg 5.4M

15.8M

vs S&P 500 Today

Strong Underperformance

-15.91%

Updated: October 23, 2026 at 20:21 UTC

Technical Indicators

2 Buy2 Neutral4 Sell

TNGX shows a mixed technical picture with short-term indicators soft while longer-term support remains intact. Momentum measures are lukewarm to slightly negative even as the MACD reads modestly positive, and the RSI sits near neutral, indicating limited directional conviction. Price trades below most short- and medium-term moving averages but remains above the 200-day level, and ADX near 14 points signals a weak trend. Volatility is elevated relative to price and on-balance volume is negative, while the classic pivot lies above the market. Technical takeaway: Neutral — short-term weakness offsets longer-term support, producing a balanced outlook.

All signals